Abstract 1838
Background
Axitinib (AX) is an orally administered selective inhibitor of vascular endothelial growth factor (VEGF) receptor (R)-1/2/3. We previously reported that AX preliminarily showed promising activity against gemcitabine (GEM)-refractory biliary tract cancer (BTC), and we conducted this trial to confirm the efficacy and safety.
Methods
This single-arm phase II trial registered patients (pts) with advanced BTC refractory to GEM-based regimens. They were treated with an initial AX dose of 5 mg twice daily. The primary endpoint was progression-free survival (PFS). The secondary endpoints were overall response rate (ORR), overall survival (OS), and safety. Plasma biomarkers were measured at baseline and 1 month after treatment.
Results
Between July 2016 and August 2017, a total of 19 pts were enrolled from 3 centers; median age was 67 (range: 44–80) years, 10 (53%) were men. The ECOG performance status was 0 for 10 pts (53%) and 1 for 9 pts (47%). Nine pts (47%) had recurrent disease after surgery, 15 (79%) received GEM + cisplatin in first-line chemotherapy, and 13 (68%) received 2 or more chemotherapy regimens before enrollment. The primary sites were gallbladder, extrahepatic bile duct, and intrahepatic bile duct in 9 (47%), 6 (32%), and 4 (21%) pts, respectively. The median PFS was 2.8 months (95% confidence interval [CI]: 2.1–4.1), the ORR was 5.3% (95% CI: 0.0–15.3), and the median OS was 5.8 months (95% CI: 3.3–9.7). Treatment-related adverse events in this study were similar to those previously reported for renal cell carcinoma or thyroid cancer; however, ascites occurred in two pts possibly due to AX. Plasma biomarkers at both time points were evaluated in 16 pts. AX was associated with significant increases in VEGF-A and decreases in sVEGFR-1/2/3. Of the baseline biomarkers, high sVEGFR-2 and sVEGFR-3 were significantly associated with longer PFS and OS, respectively. High sVEGFR-3 and low VEGF-D tended to increase PFS, and high sVEGFR-2 and low VEGF-D tended to increase OS.
Conclusions
AX exhibited modest activity against GEM-refractory BTC. This trial suggested that ascites should be monitored as an adverse event. Baseline sVEGFR-2 and sVEGFR-3 may be useful biomarkers for AX.
Clinical trial identification
UMIN000023014.
Editorial acknowledgement
Legal entity responsible for the study
Kyorin University Faculty of Medicine.
Funding
Japan Agency for Medical Research and Development.
Disclosure
N. Okano: Honoraria (self): Taiho Pharmaceutical; Honoraria (self): Merck Serono; Honoraria (self): Eisai; Honoraria (self): Ono Pharmaceutical; Honoraria (self): Yakult Honsha; Honoraria (self): Takeda; Honoraria (self): J-Pharma; Honoraria (self): Kyowa Hakko Kirin. M. Ueno: Honoraria (self), Research grant / Funding (institution): Taiho Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Yakult Honsha; Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self): Novartis; Honoraria (self): Lilly; Honoraria (self): Teijin Pharma; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Shire; Honoraria (self), Research grant / Funding (institution): Ono Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Merck Serono; Research grant / Funding (institution): Daiichi Sankyo; Research grant / Funding (institution): Eisai; Research grant / Funding (institution): MSD; Research grant / Funding (institution): NanoCarrier; Research grant / Funding (institution): Dainippon Sumitomo Pharma; Research grant / Funding (institution): Incyte; Research grant / Funding (institution): ASLAN Pharmaceuticals. C. Morizane: Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Yakult Honsha; Honoraria (self): Lilly; Honoraria (self), Research grant / Funding (institution): Nobelpharma; Honoraria (self): Fujifilm; Honoraria (self): Teijin Pharma; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Taiho Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Eisai; Advisory / Consultancy: AbbVie; Research grant / Funding (institution): Ono Pharmaceutical; Research grant / Funding (institution): J-Pharma. T. Yamanaka: Honoraria (self): Pfizer. H. Ojima: Research grant / Funding (institution): Pfizer Inc; Research grant / Funding (institution): Eli Lilly and Company; Research grant / Funding (institution): Merck Serono; Research grant / Funding (institution): Taiho Pharmaceutical. M. Ozaka: Honoraria (self): Taiho Pharmaceutical; Honoraria (self): Pfizer; Honoraria (self): Novartis; Honoraria (self): Bayer; Honoraria (self): Yakult Honsha; Honoraria (self): Eisai; Honoraria (self): EA Pharma. S. Kobayashi: Honoraria (self), Research grant / Funding (institution): Taiho Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Kyowa Hakko Kirin; Honoraria (self), Research grant / Funding (institution): Daiichi Sankyo Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Bayer; Honoraria (self), Research grant / Funding (institution): Eisai; Honoraria (self): Boston Scientific; Research grant / Funding (institution): Eli Lilly; Research grant / Funding (institution): Dainippon Sumitomo Pharmaceutical; Research grant / Funding (institution): Chugai Pharma; Research grant / Funding (institution): Yakult Honsha; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Takara Bio; Research grant / Funding (institution): Merck Serono; Research grant / Funding (institution): Ono Pharmaceutical; Research grant / Funding (institution): MSD; Research grant / Funding (institution): Boeringer Ingelheim; Research grant / Funding (institution): Beigene; Research grant / Funding (institution): Takeda Pharmaceutical. Y. Nakai: Honoraria (self), Research grant / Funding (self): Taiho Pharmaceutical; Honoraria (self): Daiichi Sankyo; Honoraria (self): AstraZeneca; Research grant / Funding (self): Eisai; Research grant / Funding (self): Yakult Honsha; Research grant / Funding (self): J-Pharma. M. Ikeda: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Novartis Pharma; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Bayer Yakuhin; Research grant / Funding (institution): Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Eisai; Honoraria (self): Taiho Pharmaceutical; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Eli Lilly Japan; Research grant / Funding (institution): Yakult; Advisory / Consultancy: Otsuka Pharmaceutical; Advisory / Consultancy: Daiichi-Sankyo; Honoraria (self): Sumitomo Dainippon Pharma; Honoraria (self), Advisory / Consultancy: Teijin Pharma; Honoraria (self): EA Pharma; Honoraria (self): Kaken Pharmaceutical; Advisory / Consultancy: Shire; Honoraria (self): MSD; Advisory / Consultancy, Research grant / Funding (institution): ASLAN Pharmaceuticals; Advisory / Consultancy, Research grant / Funding (institution): Chugai Pharmaceutical; Advisory / Consultancy, Research grant / Funding (institution): Ono Pharmaceutical; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Merck Serono; Research grant / Funding (institution): Nano Carrier; Honoraria (self): Gilead; Advisory / Consultancy: Astellas Pharma; Research grant / Funding (institution): Takeda Pharmaceutical; Research grant / Funding (institution): J-Pharma; Advisory / Consultancy: Micron. S. Maeno: Honoraria (self): Pfizer. F. Nagashima: Speaker Bureau / Expert testimony, Research grant / Funding (institution): Taiho; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Ono; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Merck Serono; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Takeda; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Chugai Pharma; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Yakult Honsha; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Sumitomo Dainippon; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Kyowa Hakko Kirin; Speaker Bureau / Expert testimony: Mitsubishi Tanabe Pharma; Speaker Bureau / Expert testimony: Nestle health science; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Janssen; Research grant / Funding (institution): Oncotherapy; Research grant / Funding (institution): Zeria Pharmaceutical; Research grant / Funding (institution): Lilly Japan; Research grant / Funding (institution): Daiichi Sankyo; Research grant / Funding (institution): Shionogi; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): J-Pharma; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Mochida Pharmaceutical Co. Ltd.; Research grant / Funding (institution): Astellas Pharma; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): MSD; Research grant / Funding (institution): Eisai; Research grant / Funding (institution): Nano Carrier; Research grant / Funding (institution): Shire. T. Okusaka: Honoraria (self), Research grant / Funding (self), Research grant / Funding (institution): Novartis Pharma; Honoraria (self), Research grant / Funding (self), Research grant / Funding (institution): Ono Pharmaceutical; Honoraria (self), Research grant / Funding (self), Research grant / Funding (institution): Eisai; Honoraria (self), Research grant / Funding (self), Research grant / Funding (institution): Eli Lilly Japan; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Taiho Pharmaceutical; Honoraria (self): Yakult Honsha; Honoraria (self): Teijin Pharma; Honoraria (self): Shire; Honoraria (self): AbbVie; Honoraria (self), Advisory / Consultancy: Daiichi Sankyo; Honoraria (self): Takeda Pharmaceutical; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Dainippon Sumitomo Pharma; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Bristol-Myers; Research grant / Funding (self), Research grant / Funding (institution): Pfizer Japan; Research grant / Funding (self): Kyowa Hakko Kirin; Research grant / Funding (self), Research grant / Funding (institution): AstraZeneca; Research grant / Funding (self), Research grant / Funding (institution): Chugai Pharmaceutical; Research grant / Funding (self), Research grant / Funding (institution): Nano Carrier; Research grant / Funding (self), Research grant / Funding (institution): Baxter. J. Furuse: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Eisai; Honoraria (self), Research grant / Funding (self): Bayer Yakuhin; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Taiho Pharmaceutical; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Ono Pharmaceutical; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Research grant / Funding (self): Yakult Honsha; Honoraria (self): Teijin Pharma; Honoraria (self): Shionogi; Honoraria (self): EA Pharma; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Eli Lilly Japan; Honoraria (self), Research grant / Funding (self): Takeda; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Chugai Pharma; Honoraria (self), Research grant / Funding (self): Mochida Pharmaceutical; Honoraria (self): Nihon Servier; Honoraria (self), Research grant / Funding (self): Sanofi; Honoraria (self), Advisory / Consultancy: Fujifilm; Honoraria (self): Nobel Pharma; Honoraria (self), Research grant / Funding (self): Pfizer; Honoraria (self): Sawai Pharmaceutical; Honoraria (self), Research grant / Funding (self): Daiichi Sankyo; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Sumitomo Dainippon; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Astellas Pharma; Honoraria (self), Advisory / Consultancy: Merck Serono; Honoraria (self): Nippon Kayaku; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): MSD; Honoraria (self), Advisory / Consultancy: Shire; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): AstraZeneca; Honoraria (self), Advisory / Consultancy: J-Pharma; Honoraria (self), Advisory / Consultancy: AbbVie; Honoraria (self), Research grant / Funding (self): Kyowa Hakko Kirin; Advisory / Consultancy: Takara Bio; Advisory / Consultancy: Otsuka; Research grant / Funding (self): Nano Carrier. All other authors have declared no conflicts of interest.
Resources from the same session
3911 - Defining a SUV decrease cut-off in PET/CT response monitoring after one cycle of preoperative breast cancer chemotherapy
Presenter: Marcin Kubeczko
Session: Poster Display session 2
Resources:
Abstract
1849 - Effect of thioredoxin 1 quantity detection to complement the mammography in breast cancer diagnosis
Presenter: Younju Lee
Session: Poster Display session 2
Resources:
Abstract
2221 - Identification of ultralow risk breast cancer patients (probable overdiagnosis)
Presenter: Salvador Gamez Casado
Session: Poster Display session 2
Resources:
Abstract
5291 - Prevalence of Vitamin D3 deficiency among women with early breast cancer receiving chemotherapy in an oncology dayward.
Presenter: Warner Finstad
Session: Poster Display session 2
Resources:
Abstract
4247 - Changes in ER pathway activity score during neoadjuvant letrozole to assess therapy response and predict disease free survival (DFS) in ER positive breast cancer patients
Presenter: Arran Turnbull
Session: Poster Display session 2
Resources:
Abstract
568 - Second primary malignancies in patients with breast cancer.
Presenter: Carlos Erasun Lecuona
Session: Poster Display session 2
Resources:
Abstract
1428 - Phase II randomized trial of neoadjuvant trastuzumab and pertuzumab (TP) with either palbociclib + letrozole (Pal+L) or paclitaxel (Pac) for elderly patients with estrogen receptor & HER2 positive (ER+/HER2+) Breast Cancer (BC) (International Breast Cancer Study Group IBCSG 55-17, TOUCH)
Presenter: Laura Biganzoli
Session: Poster Display session 2
Resources:
Abstract
1479 - Neoadjuvant HER2-targeted therapy with or without immunotherapy with pembrolizumab (neoHIP): an open label randomized phase 2 trial
Presenter: Heather McArthur
Session: Poster Display session 2
Resources:
Abstract
1481 - A randomized phase 2 study of peri-operative ipilimumab, nivolumab and cryoablation versus standard care in women with residual, early stage/resectable, triple negative breast cancer after standard-of-care neoadjuvant chemotherapy
Presenter: Heather McArthur
Session: Poster Display session 2
Resources:
Abstract
4334 - ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in early stage triple negative breast cancer.
Presenter: Michail Ignatiadis
Session: Poster Display session 2
Resources:
Abstract